Vision Institute

Paris, France

Vision Institute

Paris, France

Time filter

Source Type

PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


News Article | May 22, 2017
Site: www.prweb.com

The LASIK Vision Institute, industry leader in laser eye surgery, announced today that it has opened a new facility in Provo, Utah. This state-of-the-art center will offer solutions for a myriad of vision problems, including nearsightedness, farsightedness and astigmatism. Equipped with the latest in vision correction technology, the Provo LVI center will provide high quality eye care for an affordable price. As with all LVI centers, the LASIK team is highly trained and attentive, and the respected independent surgeons are experts in performing these FDA-approved procedures. With centers throughout the United States, LVI is committed to providing safe and convenient care. LVI surgeons across the company have collectively performed more than 1.1 million vision correction procedures, and the number of happy customers is quickly growing. There is one LVI facility already operating in Salt Lake City, and the Provo center is the second LVI in Utah. The center will serve the people of Provo and the surrounding communities of Orem, Lindon, Pleasant Grove and Vineyard. “We are thrilled to be expanding into Provo, and are looking forward to helping the people of Utah get the great eye care they deserve,” said LVI CEO Ben Cook. “It’s amazing how much your life can improve just by seeing better, and it’s our goal to help people see better.” The Provo LVI facility will be located at 898 North 1200 West, Suite 103, Orem UT, 84057, right off Veterans Memorial Highway. Interested patients should call today to set up free, no-obligation evaluation. For eligible patients, LVI offers easy financing options that make vision correction attainable at every budget. The top national provider of laser eye surgery, The LASIK Vision Institute (LVI) operates a growing nationwide network. The company utilizes safe, FDA-approved, advanced LASIK technology. LVI’s highly skilled LASIK surgeons have performed more than one million procedures. For more information, visit The LASIK Vision Institute.


News Article | May 1, 2017
Site: www.prweb.com

Dr. Farooq Ashraf, medical director of the Atlanta Vision Institute, is pleased to announce that starting May 1, he will be offering the SMILE procedure to patients wishing to reduce or eliminate myopia (nearsightedness). SMILE – short for Small Incision Lenticule Extraction – is an innovative, new method of performing laser eye surgery which combines the benefits of PRK (photorefractive keratectomy) and LASIK (laser-assisted in-situ keratomileusis). Like LASIK, SMILE surgery is bladeless, however it requires no laser tissue ablation. Like PRK, SMILE is “flapless” (meaning no large flap is created), which contributes to quicker healing, and may make it a viable option for patients who have thin corneas and cannot undergo LASIK. “Being both bladeless and flapless, SMILE has the potential of being a safer procedure than LASIK, with less pain and discomfort than either PRK or LASIK,” Dr. Ashraf says. SMILE was developed by Zeiss, a German manufacturer of optical systems and lasers. This technology was approved for use in the United States by the Food and Drug Administration in September 2016. The Atlanta Vision Institute is among the first eye clinics in the U.S. and the first in Atlanta to perform this procedure commercially. Dr. Ashraf has experience performing SMILE overseas. He is the medical director of the Atlanta Vision Clinic in Dubai, UAE. Dr. Ashraf introduced SMILE to his patients there when the UAE approved the technology many years ago. During the SMILE procedure, computer-guided, highly-focused laser light is used to create a lenticule (a disc-shaped piece of tissue within the cornea), which is then extracted through a tiny keyhole incision. This removal of tissue reshapes the cornea, correcting the nearsightedness. SMILE surgery takes less than 5 minutes, with minimal recovery time afterwards; most patients are able to resume regular activities within 24 hours after treatment. “SMILE is a groundbreaking milestone in laser vision correction for people who have always wanted freedom from eye glasses and contact lenses, but may have been scared of the LASIK procedure,” Dr. Ashraf says. “SMILE adds an additional treatment modality and I am very pleased to be able to offer this technology to my patients in Atlanta.” To learn more about SMILE bladeless, flapless laser vision correction, or to schedule a consultation with Dr. Ashraf, please call the Atlanta Vision Institute at (770) 622-2488 or visit the Atlanta Vision Institute’s website at https://www.atlanta2020.com/. About the Atlanta Vision Institute: Dr. Ashraf is the founder of the Atlanta Vision Institute and is a board-certified ophthalmologist who specializes in corneal and refractive surgery, as well as other treatments for astigmatism, glaucoma, cataracts and other eye conditions. He obtained his advanced training in ocular surgery at Johns Hopkins University and has performed over 40,000 LASIK procedures. In addition to his Atlanta practice, Dr. Ashraf has also founded the Atlanta Vision Clinic in Dubai, UAE. For more information, visit https://www.atlanta2020.com/.


News Article | October 28, 2016
Site: www.prweb.com

The LASIK Vision Institute (LVI) announced today that it is opening a new laser eye surgery center in Lubbock, Texas. LVI has more than 70 LASIK centers in the United States, and the company has performed more than 1.1 million laser vision correction procedures. The new LASIK center in Lubbock is equipped with state-of-the-art technology to ensure the best possible care for each patient. LVI’s highly trained and experienced independent surgeons will help eligible patients improve their vision and enjoy more of their lives with less dependency on glasses or contacts. “Safe, affordable and high-quality vision correction is an incredible service that we offer,” said CEO Ben Cook. “Enjoying more activities with less reliance on contacts of glasses has made life easier for me and for many of the patients we have helped at LVI locations nationwide.” The Lubbock LASIK center will also service the neighboring towns of Guthrie, Plainview, Midland, Sweetwater, Abilene and many others. The center, the eighth LVI facility in Texas, will be located at 5307 West Loop 289 Suite 105, Lubbock, TX 79414. Patients interested in learning more about LVI’s services are encouraged to schedule a free LASIK evaluation. The top national provider of laser vision correction, The LASIK Vision Institute (LVI) operates a growing nationwide network. The company utilizes safe, FDA approved, advanced LASIK technology. LVI’s highly skilled LASIK surgeons have performed more than one million procedures. For more information, visit The LASIK Vision Institute.


ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces the successful completion of its SARA-PK clinical study for Sarconeos, lead drug candidate for the treatment of sarcopenia. The results of the study, conducted in young and elderly healthy volunteers, confirmed Sarconeos’ appropriate safety profile, with no serious adverse events associated with the administration of Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “The successful outcome of the SARA-PK study is an important milestone for BIOPHYTIS and our Sarconeos development program. We have strong confidence in Sarconeos’ safety profile and will move forward with our Phase 2b SARA-INT study in 2017, as planned.  We believe Sarconeos is well differentiated and has significant potential to treat sarcopenia, a debilitating muscle wasting disease that is largely untreatable today.” The objective of the SARA-PK study was to assess the safety, tolerability and pharmacokinetic profile of Sarconeos in elderly healthy volunteers (> 65 years old).  The study was conducted in two phases: single ascending dose (SAD) administration, and multiple ascending dose (MAD) administration.  The MAD portion of the study was aimed at evaluating the safety and pharmacokinetics of Sarconeos in 30 older subjects, following three ascending oral administrations daily for 14 days (350mg/day, 700 mg/day then 900 mg/day).  Both phases of the SARA-PK study have now been successfully completed. The results of the SARA-PK study will be used to select the two doses of Sarconeos for further evaluation in the Phase 2b SARA-INT trial, which BIOPHYTIS intends to initiate in the first half of 2017. The complete results of the SARA-PK study, in particular the pharmacokinetic profile of Sarconeos, will be available in the first quarter of 2017. Initial study results will be presented at the 9th International Conference on Sarcopenia, Cachexia, and muscle Wasting Diseases (SCWD), being held December 10-11, 2016, in Berlin, Germany. About SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people. This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). For more information: http://www.biophytis.com BIOPHYTIS is eligible for the Equity Saving Plans PEA-PME. Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


The International Association of HealthCare Professionals is pleased to welcome Kinga Michelle Huzella, MD, Ophthalmologist, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. She is a highly-trained and qualified ophthalmologist with an extensive expertise in all facets of her work, especially glaucoma and cornea treatments. Dr. Kinga Michelle Huzella has been in practice for more than 25 years and is currently serving patients at Maryland Vision Institute in Hagerstown, Maryland. Dr. Kinga Michelle Huzella’s career in medicine began in 1991 when she graduated with her Medical Degree from the Jacobs School of Medicine at the State University of New York at Buffalo. Following her graduation, Dr. Huzella went on to complete her internship at the University of Virginia Health Sciences Center, followed by her residency at New York’s Brookdale University Hospital and Medical Center, where she served as Chief Resident. Furthermore, Dr. Huzella is board certified by the American Board of Ophthalmology. To keep up to date with the latest advances and developments in her field, Dr. Huzella maintains a professional membership with the American Academy of Ophthalmology, the Maryland Society of Eye Physicians and Surgeons, the Hungarian Medical Association of America, and Women in Ophthalmology. Dr. Huzella attributes her success to the love and encouragement of her parents, her great work ethic, her passion and compassion for her patients, and the support from her husband. When she is not assisting her patients, Dr. Huzella enjoys playing the piano, animals, traveling, aerobics, jogging, tennis, and spending time with her family. Learn more about Dr. Huzella by reading her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics.  Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review.  FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise.  A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life.  For more information about FindaTopDoc, visit http://www.findatopdoc.com


PARIS, March 02, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today the complete results of the SARA-PK study, in particular the favorable pharmacokinetics and pharmacodynamics of Sarconeos. The analyses confirm the good pharmacokinetic profile in healthy elderly volunteers, the therapeutic window of Sarconeos, and confirms the dosages that will be tested in the Phase 2b trial SARA-INT. The study’s complete results will be presented at the International ICFSR on April 28th in Barcelona. Stanislas Veillet, CEO of BIOPHYTIS, declares: “The analysis of the complete results of the SARA-PK trial confirms Sarconeos’ good pharmacokinetic profile and allows us to determine the doses that will be tested in the Phase 2b study, SARA-INT, which we hope to start in mid-2017. These data will be used now to complete the regulatory filings required for the authorizations to start in U.S. and Europe SARA-INT, the interventional Phase 2b trial in sarcopenia patients." Safety data collected at the end of SARA-PK had already confirmed the good tolerability profile and the absence of any serious adverse event associated with the administration of Sarconeos. These safety results had already been presented at the 9th international conference on Cachexia, Sarcopenia and muscle Wasting Disease (SCWD) held in Berlin last December. The complete results of the SARA-PK study, in particular the pharmacokinetic profile of the Sarconeos product, have now been analyzed and top-line data are being communicated today for the first time. The main parameters of the pharmacokinetics (half-life, area under curve, maximum plasma concentration of the product, etc.) have been estimated, allowing the confirmation of Sarconeos’ good pharmacokinetic profile in healthy elderly volunteers, which is not significantly different from the profile observed in adult volunteers. The qualitative study of biomarkers of muscular metabolism (creatine kinase, myoglobin, etc.) and of the renin-angiotensin system (renin, adolsterone, etc.) gathered at the end of the trial, allows for the description of Sarconeos’ pharmacodynamic profile. The study of Sarconeos’ effects on these biomarkers in SARA-INT should allow the confirmation of these patterns. The complete analysis of the safety, pharmacokinetic and pharmacodynamic data allows the confirmation of Saconeos’ favorable therapeutic window and the selection of the two doses which will be tested in the placebo-controlled Phase 2b SARA-INT trial, provided it is authorized by the relevant regulatory agencies. The selected oral doses are: 175 mg twice-daily and 350mg twice-daily. The complete results of the SARA-PK study will be presented in an oral presentation at the ICFSR (International Conference on Frailty & Sarcopenia Research), which will take place in Barcelona from April 27th to 29th of. The title of the presentation will be: “SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers”. An abstract of the presentation also will be published in a special edition of the scientific review The Journal of Frailty & Aging. About SARA-PK: The objective of the SARA-PK study was to evaluate safety, tolerance and the pharmacokinetic profile of Sarconeos in healthy elderly volunteers (>65 years). The study was carried out in two phases: the administration of a single ascending dose (SAD), and multiple ascending doses (MAD). The second stage of the study – MAD (multiple ascending doses) – which has just been reached, had as its objective the evaluation of the safety, tolerance and pharmacokinetics of Sarconeos in subjects aged 30, after the oral administration of 3 multiple ascending doses (350mg/day, 700 mg/day then 900 mg/day) every day over 14 days. Both phases of the SARA-PK study were carried out successfully. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). Located on the Pierre et Marie Curie University (UPMC) campus in Paris, BIOPHYTIS also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). For more information: http://www.biophytis.com BIOPHYTIS is eligible for the SMEs scheme. Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging, announced today that four posters on Sarconeos (BIO101), the Company’s lead drug candidate for the treatment of sarcopenia, have been accepted for presentation at the 9th International Conference on Cachexia, Sarcopenia and Muscle Wasting, being held December 10-11, 2016 in Berlin, Germany. Stanislas Veillet CEO BIOPHYTIS, said: "Sarcopenia, or muscle wasting, is a growing problem as the world population continues to age and live longer. Having four poster presentations focusing on Sarconeos at a conference specifically tailored to and attended by key opinion leaders in muscular dystrophies is the perfect opportunity to showcase to key opinion leaders its method of action, clinical development, and patient outcomes observed to date.” About The Society on Sarcopenia, Cachexia, and Wasting Disorders (SCWD) The Society on Sarcopenia, Cachexia, and Wasting Disorders was founded in 2008 on the initiative of Dr. Stefan D. Anker and Dr. John E. Morley, whose leadership and vision guided the expansion of clinical expertise and research in this field. The Society on Sarcopenia, Cachexia and Wasting Disorders is a non-profit scientific organization comprised of an international and multidisciplinary group of health-care professionals primarily active in these fields. The SCWD seeks to further research on cachexia and sarcopenia and wasting disorders and bring practical solutions to health-care teams worldwide grappling with treatment. The spectrum of clinical disorders represented by the SCWD Society includes, but is not limited to cachexia, sarcopenia, the syndrome of muscle wasting associated to cancer, COPD, diabetes, heart failure, aging and other chronic conditions.  In recent years, there has been tremendous growth in new diagnostic information, pharmacological and nutritional treatments for wasting disorders, as well as a greater number of associated clinical trials. About SARCONEOS (BIO101) Sarconeos is a first in class drug candidate based on the activation of the Mas receptor (major player of the renin-angiotensin system) restoring muscular anabolism, inhibiting myostatin, that has demonstrated meaningful activity in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle, leading to loss of mobility in elderly people. This condition, for which no medical treatment currently exists, was first described in 1993 and has entered the International Classification of Diseases (M62.84) in 2016. It affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.BIOPHYTIS.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN:FR0012816825). Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.BIOPHYTIS.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Loading Vision Institute collaborators
Loading Vision Institute collaborators